Brief: JCR Pharmaceuticals Announces Licensing Agreement With Menagen To Commercialize Agalsidase Beta BS I.V. Infusion
01/10/2025 18:37
Oct 1 (Reuters) - JCR Pharmaceuticals Co Ltd 4552.T: JCR PHARMACEUTICALS ANNOUNCES LICENSING AGREEMENT WITH MENAGEN TO COMMERCIALIZE AGALSIDASE BETA BS I.V. INFUSION JCR ACROSS NINE MENAT MARKETS JCR PHARMACEUTICALS CO LTD: DOES NOT EXPECT A MATERIAL IMPACT ON FY2025 CONSOLIDATED RESULTS FROM MENAGEN DEAL Source text: ID:nBw1hK4ZVa Further company coverage: 4552.T (((( Reuters.Briefs@thomsonreuters.com ;));))
Recent news on JCR Pharmaceuticals
See all newsBrief: JCR Pharmaceuticals Receives Marketing Authorization In Kuwait For Izcargo
Italfarmaco And Jcr Pharmaceuticals Enter Into Exclusive License Agreement For Jr-141 In United States, Europe, And Latin America
Brief: Jcr Pharmaceuticals Receives Orphan Drug Designation For Givinostat In Japan
Brief: Medipal & JCR Dose First Patient In Global Phase I/II Trial OF JR-446 For Mucopolysaccharidosis Type IIIB
Table: Jcr Pharmaceuticals -Q1 group results